[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA26511A1 - PHARMACEUTICAL COMPOSITIONS COMPRISING 5- (4- (2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY) BENZYL) -THIAZOLIDINE-2,4-DIONE AND INSULIN FOR A TREATMENT METHOD. - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING 5- (4- (2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY) BENZYL) -THIAZOLIDINE-2,4-DIONE AND INSULIN FOR A TREATMENT METHOD.

Info

Publication number
MA26511A1
MA26511A1 MA25122A MA25122A MA26511A1 MA 26511 A1 MA26511 A1 MA 26511A1 MA 25122 A MA25122 A MA 25122A MA 25122 A MA25122 A MA 25122A MA 26511 A1 MA26511 A1 MA 26511A1
Authority
MA
Morocco
Prior art keywords
thiazolidine
dione
pyridyl
insulin
ethoxy
Prior art date
Application number
MA25122A
Other languages
French (fr)
Inventor
Dr Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26511A1 publication Critical patent/MA26511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25122A 1997-06-18 1998-06-17 PHARMACEUTICAL COMPOSITIONS COMPRISING 5- (4- (2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY) BENZYL) -THIAZOLIDINE-2,4-DIONE AND INSULIN FOR A TREATMENT METHOD. MA26511A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
MA26511A1 true MA26511A1 (en) 2004-12-20

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25122A MA26511A1 (en) 1997-06-18 1998-06-17 PHARMACEUTICAL COMPOSITIONS COMPRISING 5- (4- (2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY) BENZYL) -THIAZOLIDINE-2,4-DIONE AND INSULIN FOR A TREATMENT METHOD.

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR015894A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265D0 (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
PE20010040A1 (en) 1999-04-23 2001-03-10 Smithkline Beecham Plc SALT POLYMORPH OF MALEIC ACID OF 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY] BENZYL] -THAZOLIDINE-2,4-DIONA
USRE40876E1 (en) * 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
EP1196189A2 (en) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2312106C2 (en) * 2002-11-08 2007-12-10 Ф.Хоффманн-Ля Рош Аг Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2171827C (en) * 1993-09-15 2004-06-29 Jerrold Olefsky Use of thiazolidinediones to prevent or delay onset of niddm
KR19990036290A (en) * 1995-08-10 1999-05-25 로즈 암스트롱 Reduction of Exogenous Insulin Dosage in Non-insulin-Dependent Diabetic Patients
DK0859608T3 (en) * 1995-09-18 2004-06-14 Ligand Pharm Inc Treatment of NIDDM with RXR agonists

Also Published As

Publication number Publication date
TR199903095T2 (en) 2000-08-21
PE104499A1 (en) 2000-01-13
UY25050A1 (en) 2000-09-29
ID23951A (en) 2000-06-08
EP0999837A1 (en) 2000-05-17
JP2002504138A (en) 2002-02-05
AR015894A1 (en) 2001-05-30
CO4940454A1 (en) 2000-07-24
CN1133431C (en) 2004-01-07
SK179399A3 (en) 2000-11-07
WO1998057636A1 (en) 1998-12-23
HUP0003260A3 (en) 2001-12-28
DZ2521A1 (en) 2003-02-08
CN1260715A (en) 2000-07-19
KR20010013843A (en) 2001-02-26
GB9712866D0 (en) 1997-08-20
NO996265L (en) 1999-12-17
BG104059A (en) 2000-10-31
OA11517A (en) 2004-02-04
PL343123A1 (en) 2001-07-30
AP9901718A0 (en) 1999-12-31
UA70299C2 (en) 2004-10-15
AR012997A1 (en) 2000-11-22
IL133143A0 (en) 2001-03-19
AU8216398A (en) 1999-01-04
NO996265D0 (en) 1999-12-17
EA004800B1 (en) 2004-08-26
CA2294141A1 (en) 1998-12-23
TW587937B (en) 2004-05-21
IN189723B (en) 2003-04-19
AP1287A (en) 2004-06-26
BR9810444A (en) 2000-09-05
ZA985237B (en) 2000-02-17
HUP0003260A2 (en) 2001-05-28
EA200000042A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
MA26511A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING 5- (4- (2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY) BENZYL) -THIAZOLIDINE-2,4-DIONE AND INSULIN FOR A TREATMENT METHOD.
EA200601145A1 (en) TABLET OF SLOW-DIVISION OF INSULIN SENSITIZER AND OTHER ANTI-DIABETIC AGENTS
IL146111A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
IL136424A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
IL155036A0 (en) Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
IL136381A (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy] benzyl] thiazolidine-2,4-dione maleic acid salt, its preparation and pharmaceutical compositions comprising it
HUP0004070A2 (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HUP0003397A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes
CY1105354T1 (en) A THIAZOLIDINODIONE DERIVATIVE AND ITS USE AS AN ANTI-DIABETIC
AU2002343036A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DE60212434D1 (en) ROSIGLITAZONE EDISYLATES AND THEIR USE AS ANTIDIABETICS
DK1349855T3 (en) 5- (4- (2- (N-methyl-N- (2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dionmesylatsalt
MXPA02012100A (en) Thiazolidinedione salt for treatment of diabetes mellitus.
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
BR0112982A (en) Thiazolidinedione derivative tartrate salt
HK1068884A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyleof; and its use as pharmaceutical active ingredie)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thernt